DESIGNING OF COUMARIN ANALOGS: A NEW INSIGHT AS ENOL ACYL CARRIER PROTEIN REDUCATSE INHIBITORS

Abstract

Tuberculosis was almost certainly the leading cause of death in Europe and the United States in recorded history, although because of the multifarious forms of the disease. Based on literature we have designed coumarin linked with thiadiazole derivatives as antitubercular agents. To determine structural requirements, we carried out molecular docking study in which we found that our designed molecule have similar binding with enoyl acyl carrier protein reductase (InhA). The docking studies results showed that the compound 6, 15 and 27 showed more binding energy with InhA mutant than that of reference compound Isoniazid.

Keywords: Tuberculosis, InhA, Coumarin, Molecular modeling

Cite this Article

Monika Kakadiya, Mogal Azmin, Malleshappa N. Noolvi. Designing of Coumarin Analogs: A New Insight as Enol Acyl Carrier Protein Reducatse Inhibitors, 2019. Research & Reviews: A Journal of Drug Design & Discovery. 2019; 6(2): 1–5p